Impact of a VI-polysaccharide conjugate vaccine in preventing Typhoid Fever in an endemic setting, Lalitpur, Nepal
<p>Globally, an estimated 11 to 21 million cases of febrile illness and 117,000 to 161,000 deaths are attributed to typhoid fever each year. Typhoid fever is prevalent mainly in low-resource settings with poor water, and inadequate sanitation and hygiene facilities, with South Asia accounting...
Päätekijä: | Shakya, M |
---|---|
Muut tekijät: | Pollard, A |
Aineistotyyppi: | Opinnäyte |
Kieli: | English |
Julkaistu: |
2022
|
Aiheet: |
Samankaltaisia teoksia
-
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Tekijä: Maile T. Phillips, et al.
Julkaistu: (2023-03-01) -
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial
Tekijä: Sodiomon B. Sirima, et al.
Julkaistu: (2021-07-01) -
Costs of typhoid vaccination for international travelers from the United States
Tekijä: Heesoo Joo, et al.
Julkaistu: (2025-03-01) -
Single and two-dose typhoid conjugate vaccine safety and immunogenicity in HIV-exposed uninfected and HIV-unexposed uninfected Malawian children
Tekijä: Nginache Nampota-Nkomba, et al.
Julkaistu: (2024-12-01) -
Global diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 Salmonella Typhi genomes
Tekijä: Megan E Carey, et al.
Julkaistu: (2023-09-01)